menu
    • menu
    [{"orgOrder":0,"company":"Piramal Enterprises Limited","sponsor":"Melanoma Research Foundation Breakthrough Consortium","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"INDIA","productType":"Miscellaneous","year":"2013","type":"Inapplicable","leadProduct":"Voruciclib","moa":"Cyclin-dependent kinase 4","graph1":"Oncology","graph2":"Phase I","graph3":"Piramal Enterprises Limited","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Piramal Enterprises Limited \/ Melanoma Research Foundation Breakthrough Consortium","highestDevelopmentStatusID":"6","companyTruncated":"Piramal Enterprises Limited \/ Melanoma Research Foundation Breakthrough Consortium"},{"orgOrder":0,"company":"Piramal Enterprises Limited","sponsor":"Dana-Farber Cancer Institute | Norris Cotton Cancer Center","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"INDIA","productType":"Miscellaneous","year":"2014","type":"Inapplicable","leadProduct":"Voruciclib","moa":"Cyclin-dependent kinase 4","graph1":"Oncology","graph2":"Phase I","graph3":"Piramal Enterprises Limited","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Piramal Enterprises Limited \/ Dana-Farber Cancer Institute | Norris Cotton Cancer Center","highestDevelopmentStatusID":"6","companyTruncated":"Piramal Enterprises Limited \/ Dana-Farber Cancer Institute | Norris Cotton Cancer Center"},{"orgOrder":0,"company":"Piramal Enterprises Limited","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"INDIA","productType":"Miscellaneous","year":"2011","type":"Inapplicable","leadProduct":"P276-00","moa":"Cyclin-dependent kinase 4 | Cyclin-dependent kinase 9 | Cyclin-dependent kinase 1","graph1":"Oncology","graph2":"Phase I","graph3":"Piramal Enterprises Limited","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Piramal Enterprises Limited \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Piramal Enterprises Limited \/ Undisclosed"},{"orgOrder":0,"company":"Piramal Enterprises Limited","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"INDIA","productType":"Miscellaneous","year":"2013","type":"Inapplicable","leadProduct":"P276-00","moa":"Cyclin-dependent kinase 4 | Cyclin-dependent kinase 9 | Cyclin-dependent kinase 1","graph1":"Oncology","graph2":"Phase II","graph3":"Piramal Enterprises Limited","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Piramal Enterprises Limited \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Piramal Enterprises Limited \/ Undisclosed"},{"orgOrder":0,"company":"Piramal Enterprises Limited","sponsor":"Quintiles Inc | Miami Research Associates","pharmaFlowCategory":"DU","therapeuticArea":"Nutrition and Weight Loss","country":"INDIA","productType":"Undisclosed","year":"2013","type":"Inapplicable","leadProduct":"P11187","moa":"Free fatty acid receptor 1 (GPR40)","graph1":"Nutrition and Weight Loss","graph2":"Phase I","graph3":"Piramal Enterprises Limited","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Piramal Enterprises Limited \/ Quintiles Inc | Miami Research Associates","highestDevelopmentStatusID":"6","companyTruncated":"Piramal Enterprises Limited \/ Quintiles Inc | Miami Research Associates"},{"orgOrder":0,"company":"Piramal Enterprises Limited","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"INDIA","productType":"Undisclosed","year":"2011","type":"Inapplicable","leadProduct":"Tinefcon","moa":"Immune","graph1":"Dermatology","graph2":"Phase IV","graph3":"Piramal Enterprises Limited","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Piramal Enterprises Limited \/ Undisclosed","highestDevelopmentStatusID":"11","companyTruncated":"Piramal Enterprises Limited \/ Undisclosed"},{"orgOrder":0,"company":"Piramal Enterprises Limited","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"INDIA","productType":"Miscellaneous","year":"2013","type":"Inapplicable","leadProduct":"P7170","moa":"Serine\/threonine-protein kinase receptor R3 | PI3-kinase class I | Serine\/threonine-protein kinase mTOR","graph1":"Oncology","graph2":"Phase I","graph3":"Piramal Enterprises Limited","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Piramal Enterprises Limited \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Piramal Enterprises Limited \/ Undisclosed"},{"orgOrder":0,"company":"Piramal Enterprises Limited","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Nutrition and Weight Loss","country":"INDIA","productType":"Undisclosed","year":"2013","type":"Inapplicable","leadProduct":"P7435","moa":"TLR8","graph1":"Nutrition and Weight Loss","graph2":"Phase I","graph3":"Piramal Enterprises Limited","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Piramal Enterprises Limited \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Piramal Enterprises Limited \/ Undisclosed"},{"orgOrder":0,"company":"Piramal Enterprises Limited","sponsor":"Profil Institute for Clinical Research","pharmaFlowCategory":"DU","therapeuticArea":"Undisclosed","country":"INDIA","productType":"Undisclosed","year":"2013","type":"Inapplicable","leadProduct":"P7435","moa":"TLR8","graph1":"Undisclosed","graph2":"Phase I","graph3":"Piramal Enterprises Limited","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Piramal Enterprises Limited \/ Profil Institute for Clinical Research","highestDevelopmentStatusID":"6","companyTruncated":"Piramal Enterprises Limited \/ Profil Institute for Clinical Research"},{"orgOrder":0,"company":"Piramal Enterprises Limited","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Endocrinology","country":"INDIA","productType":"Undisclosed","year":"2012","type":"Inapplicable","leadProduct":"P2202","moa":"Undisclosed","graph1":"Endocrinology","graph2":"Phase II","graph3":"Piramal Enterprises Limited","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Piramal Enterprises Limited \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Piramal Enterprises Limited \/ Undisclosed"},{"orgOrder":0,"company":"Piramal Enterprises Limited","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dental and Oral Health","country":"INDIA","productType":"Undisclosed","year":"2011","type":"Inapplicable","leadProduct":"P3914","moa":"Undisclosed","graph1":"Dental and Oral Health","graph2":"Phase I","graph3":"Piramal Enterprises Limited","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Dental & Oral Health","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Piramal Enterprises Limited \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Piramal Enterprises Limited \/ Undisclosed"},{"orgOrder":0,"company":"Piramal Enterprises Limited","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"INDIA","productType":"Undisclosed","year":"2013","type":"Inapplicable","leadProduct":"PL225B","moa":"Undisclosed","graph1":"Oncology","graph2":"Phase I","graph3":"Piramal Enterprises Limited","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Piramal Enterprises Limited \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Piramal Enterprises Limited \/ Undisclosed"}]

    Find Clinical Drug Pipeline Developments & Deals by Piramal Enterprises Limited

    Menu

    Piramal Enterprises Limited

    EVENTS

    • Webinars & Exhibitions

    DIGITAL CONTENT

    ACTIVE PHARMA INGREDIENTS

    DEVELOPMENTS

    FINISHED DOSAGE FORMULATIONS

    SERVICES

    INSPECTIONS & REGISTRATIONS

    PharmaCompass
    Xls
    Filters Filter
    ×
    FILTER:
    filter
    Company Name
      filter

      Year

        filter

        DEALS // DEV.

          filter

          Country

            filter
            Sponsor
              filter

              Therapeutic Area

                filter

                Study Phase

                  filter

                  Deal Type

                    filter

                    Product Type

                      filter

                      Dosage Form

                        filter

                        Lead Product

                          filter

                          Target

                            Loading...
                            refresh Filters
                            refresh Reset Filter
                            refresh Reset Filter
                            price-trend All Developments

                            Therapeutic Area by Lead Product

                            Study Phase by Lead Product

                            Company by Lead Product

                            Top Deals by Deal Size (USD bn)

                            01

                            Piramal Enterprises Limited

                            India arrow
                            AIChE Annual Meeting
                            Not Confirmed

                            Piramal Enterprises Limited

                            India arrow
                            AIChE Annual Meeting
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Voruciclib

                            Therapeutic Area : Oncology

                            Study Phase : Phase I

                            Sponsor : Dana-Farber Cancer Institute | Norris Cotton Cancer Center

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Clinical Study of Relapsed/Refractory Chronic Lymphocytic Leukemia (CLL)

                            Details : P1446A-05 is a Other Small Molecule drug candidate, which is currently being evaluated in phase I clinical studies for the treatment of Leukemia, Lymphocytic, Chronic, B-Cell.

                            Product Name : Undisclosed

                            Product Type : Miscellaneous

                            Upfront Cash : Inapplicable

                            April 17, 2014

                            Lead Product(s) : Voruciclib

                            Therapeutic Area : Oncology

                            Highest Development Status : Phase I

                            Sponsor : Dana-Farber Cancer Institute | Norris Cotton Cancer Center

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            02

                            Piramal Enterprises Limited

                            India arrow
                            AIChE Annual Meeting
                            Not Confirmed

                            Piramal Enterprises Limited

                            India arrow
                            AIChE Annual Meeting
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : P7435

                            Therapeutic Area : Undisclosed

                            Study Phase : Phase I

                            Sponsor : Profil Institute for Clinical Research

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Study to Determine the Safety, Tolerability, Pharmacokinetics, Food Effect and Pharmacodynamics of Single and ...

                            Details : P7435 is a drug candidate, which is currently being evaluated in phase I clinical studies for the treatment of undefined medical condition.

                            Product Name : Undisclosed

                            Product Type : Undisclosed

                            Upfront Cash : Inapplicable

                            July 29, 2013

                            Lead Product(s) : P7435

                            Therapeutic Area : Undisclosed

                            Highest Development Status : Phase I

                            Sponsor : Profil Institute for Clinical Research

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            03

                            Piramal Enterprises Limited

                            India arrow
                            AIChE Annual Meeting
                            Not Confirmed

                            Piramal Enterprises Limited

                            India arrow
                            AIChE Annual Meeting
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : P276-00

                            Therapeutic Area : Oncology

                            Study Phase : Phase II

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            A Study to Assess Radiation Induced Mucositis in Patients of Head and Neck Cancer Administered Chemo-Radiation...

                            Details : P276-00 is a Other Small Molecule drug candidate, which is currently being evaluated in phase II clinical studies for the treatment of Radiation-induced Mucositis in Head and Neck Neoplasms.

                            Product Name : Undisclosed

                            Product Type : Miscellaneous

                            Upfront Cash : Inapplicable

                            July 19, 2013

                            Lead Product(s) : P276-00

                            Therapeutic Area : Oncology

                            Highest Development Status : Phase II

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            04

                            Piramal Enterprises Limited

                            India arrow
                            AIChE Annual Meeting
                            Not Confirmed

                            Piramal Enterprises Limited

                            India arrow
                            AIChE Annual Meeting
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : P11187

                            Therapeutic Area : Nutrition and Weight Loss

                            Study Phase : Phase I

                            Sponsor : Quintiles Inc | Miami Research Associates

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Determination of Safety,Tolerability,Pharmacokinetics,Food Effect& Pharmacodynamics of Single & Multiple Doses...

                            Details : P11187 is a drug candidate, which is currently being evaluated in phase I clinical studies for the treatment of Overweight.

                            Product Name : Undisclosed

                            Product Type : Undisclosed

                            Upfront Cash : Inapplicable

                            June 11, 2013

                            Lead Product(s) : P11187

                            Therapeutic Area : Nutrition and Weight Loss

                            Highest Development Status : Phase I

                            Sponsor : Quintiles Inc | Miami Research Associates

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            05

                            Piramal Enterprises Limited

                            India arrow
                            AIChE Annual Meeting
                            Not Confirmed

                            Piramal Enterprises Limited

                            India arrow
                            AIChE Annual Meeting
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Voruciclib

                            Therapeutic Area : Oncology

                            Study Phase : Phase I

                            Sponsor : Melanoma Research Foundation Breakthrough Consortium

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Study of an Oral Cdk Inhibitor Administered With an Oral BRAF Inhibitor in Patients With Advanced or Inoperabl...

                            Details : P1446A-05 is a Other Small Molecule drug candidate, which is currently being evaluated in phase I clinical studies for the treatment of Melanoma.

                            Product Name : Undisclosed

                            Product Type : Miscellaneous

                            Upfront Cash : Inapplicable

                            April 26, 2013

                            Lead Product(s) : Voruciclib

                            Therapeutic Area : Oncology

                            Highest Development Status : Phase I

                            Sponsor : Melanoma Research Foundation Breakthrough Consortium

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            06

                            Piramal Enterprises Limited

                            India arrow
                            AIChE Annual Meeting
                            Not Confirmed

                            Piramal Enterprises Limited

                            India arrow
                            AIChE Annual Meeting
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : PL225B

                            Therapeutic Area : Oncology

                            Study Phase : Phase I

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Clinical Study of Oral IGF-1R Inhibitor in Subjects With Advanced Refractory Solid Tumors

                            Details : PL225B is a drug candidate, which is currently being evaluated in phase I clinical studies for the treatment of Neoplasms.

                            Product Name : Undisclosed

                            Product Type : Undisclosed

                            Upfront Cash : Inapplicable

                            January 30, 2013

                            Lead Product(s) : PL225B

                            Therapeutic Area : Oncology

                            Highest Development Status : Phase I

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            07

                            Piramal Enterprises Limited

                            India arrow
                            AIChE Annual Meeting
                            Not Confirmed

                            Piramal Enterprises Limited

                            India arrow
                            AIChE Annual Meeting
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : P7435

                            Therapeutic Area : Nutrition and Weight Loss

                            Study Phase : Phase I

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Clinical Trial to Study the Safety Tolerability, Pharmacokinetics, Food Effect & Pharmacodynamics of a New Com...

                            Details : P7435 is a drug candidate, which is currently being evaluated in phase I clinical studies for the treatment of Obesity.

                            Product Name : Undisclosed

                            Product Type : Undisclosed

                            Upfront Cash : Inapplicable

                            January 09, 2013

                            Lead Product(s) : P7435

                            Therapeutic Area : Nutrition and Weight Loss

                            Highest Development Status : Phase I

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            08

                            Piramal Enterprises Limited

                            India arrow
                            AIChE Annual Meeting
                            Not Confirmed

                            Piramal Enterprises Limited

                            India arrow
                            AIChE Annual Meeting
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : P7170

                            Therapeutic Area : Oncology

                            Study Phase : Phase I

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Clinical Study of Oral PI3K/mTOR Inhibitor in Patients With Advanced Refractory Solid Tumors

                            Details : P7170 is a Other Small Molecule drug candidate, which is currently being evaluated in phase I clinical studies for the treatment of Neoplasms.

                            Product Name : Undisclosed

                            Product Type : Miscellaneous

                            Upfront Cash : Inapplicable

                            January 07, 2013

                            Lead Product(s) : P7170

                            Therapeutic Area : Oncology

                            Highest Development Status : Phase I

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            09

                            Piramal Enterprises Limited

                            India arrow
                            AIChE Annual Meeting
                            Not Confirmed

                            Piramal Enterprises Limited

                            India arrow
                            AIChE Annual Meeting
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : P2202

                            Therapeutic Area : Endocrinology

                            Study Phase : Phase II

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            A Clinical Trial to Study the Efficacy, Safety, Tolerability and Pharmacokinetics of P2202 in Patients of Type...

                            Details : P2202 is a drug candidate, which is currently being evaluated in phase II clinical studies for the treatment of Diabetes Mellitus, Type 2.

                            Product Name : Undisclosed

                            Product Type : Undisclosed

                            Upfront Cash : Inapplicable

                            August 28, 2012

                            Lead Product(s) : P2202

                            Therapeutic Area : Endocrinology

                            Highest Development Status : Phase II

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            10

                            Piramal Enterprises Limited

                            India arrow
                            AIChE Annual Meeting
                            Not Confirmed

                            Piramal Enterprises Limited

                            India arrow
                            AIChE Annual Meeting
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Tinefcon

                            Therapeutic Area : Dermatology

                            Study Phase : Phase IV

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            A Phase IV Clinical Trial to Study the Safety, Tolerability and Efficacy of Tinefcon in Patients With Plaque P...

                            Details : Tinefcon is a drug candidate, which is currently being evaluated in phase IV clinical studies for the treatment of Psoriasis.

                            Product Name : Undisclosed

                            Product Type : Undisclosed

                            Upfront Cash : Inapplicable

                            June 15, 2011

                            Lead Product(s) : Tinefcon

                            Therapeutic Area : Dermatology

                            Highest Development Status : Phase IV

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth